Engineering T cells to fight liver cancer
TCR engineering of human T cells for immunotherapy of hepatocellular carcinoma
['FUNDING_R01'] · AUGUSTA UNIVERSITY · NIH-10746423
This study is testing a new treatment for liver cancer that uses your own immune cells to better target and fight the cancer, and if you're interested, you might have the chance to join a clinical trial to see how well it works and if it's safe.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | AUGUSTA UNIVERSITY (nih funded) |
| Locations | 1 site (AUGUSTA, UNITED STATES) |
| Trial ID | NIH-10746423 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new immunotherapy for hepatocellular carcinoma (HCC), a common and deadly form of liver cancer. The approach involves modifying a patient's own T cells to recognize and attack cancer cells that express a specific protein called alpha-fetoprotein (AFP). By creating a variety of T cell receptors (TCRs) with different affinities for AFP, the researchers aim to enhance the effectiveness of the immune response while minimizing potential side effects. Patients may have the opportunity to participate in clinical trials testing these engineered T cells for their safety and efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with hepatocellular carcinoma who have not responded to standard treatments.
Not a fit: Patients with liver cancer types other than hepatocellular carcinoma or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a targeted immunotherapy option for patients with liver cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using engineered T cells for cancer treatment, indicating that this approach could be a viable option for liver cancer as well.
Where this research is happening
AUGUSTA, UNITED STATES
- AUGUSTA UNIVERSITY — AUGUSTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HE, YUKAI — AUGUSTA UNIVERSITY
- Study coordinator: HE, YUKAI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers